<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660929</url>
  </required_header>
  <id_info>
    <org_study_id>101</org_study_id>
    <nct_id>NCT04660929</nct_id>
  </id_info>
  <brief_title>CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors</brief_title>
  <official_title>A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects With HER2 Overexpressing Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carisma Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carisma Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid&#xD;
      tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered&#xD;
      to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects with HER2 Overexpressing Solid&#xD;
      Tumors&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety and tolerability of CT-0508 by estimating the frequency and severity of adverse events in subjects with HER2 overexpressing solid tumors.</measure>
    <time_frame>14 months</time_frame>
    <description>Frequency and severity of adverse events including, but not limited to, estimating frequency and severity of Cytokine Release Syndrome (CRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the feasibility of manufacturing CT-0508 by describing the percentage of products passing release criteria.</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of products that pass release criteria among all manufactured products.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the objective response rate (ORR), according to RECIST v1.1, of at least 1 dose of CT-0508 among subjects with HER2 overexpressing solid tumors.</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of subjects with an objective response (either a complete response [CR] or partial response [PR]) in subjects who received at least 1 dose of CT-0508 and at least the 8-week tumor evaluation as determined by the investigator using RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate progression-free survival (PFS).</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as the time between the date of first dose and the date of first documented disease progression as determined by the investigator using RECIST v1.1 or death due to any cause, whichever occurs first.&#xD;
Defined as the time between the date of first dose and the date of first documented disease progression as determined by the investigator using RECIST v1.1 or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>HER2-positive</condition>
  <condition>Adenocarcinoma</condition>
  <condition>Bile Duct Cancer</condition>
  <condition>Biliary Tract Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Breast Neoplasm</condition>
  <condition>Carcinoma, Ductal</condition>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Cancer</condition>
  <condition>Lung Cancer, Non-Small-Cell</condition>
  <condition>Carcinoma, Ovarian Epithelial</condition>
  <condition>Carcinoma, Small Cell</condition>
  <condition>Carcinoma, Squamous</condition>
  <condition>Carcinoma, Transitional Cell</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Esophagogastric Junction Neoplasms</condition>
  <condition>Inflammatory Breast Cancer</condition>
  <condition>Stomach Neoplasms</condition>
  <condition>Malignant Neoplasms</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>HER2-positive Solid Tumors</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>HER2-positive Gastric Cancer</condition>
  <condition>HER-2 Protein Overexpression</condition>
  <condition>HER-2 Gene Amplification</condition>
  <condition>Prostate Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Lung Cancer, Small Cell</condition>
  <arm_group>
    <arm_group_label>Group 1 and Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Both groups will receive the full dose manufactured per patient. Group 1 will undergo intra subject dose escalation of IV administrations of up to 500 million total cells on Day 1, up to 1.5 billion total cells on Day 3, and up to 3.0 billion total cells on Day 5. Group 2 will receive the full dose IV on Day 1 of up to 5 billion cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-0508</intervention_name>
    <description>anti-HER2 CAR macrophages</description>
    <arm_group_label>Group 1 and Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HER2-positive recurrent or metastatic solid tumors for which there are no available&#xD;
             curative treatment options.&#xD;
&#xD;
               -  Breast cancer and gastric/gastroesophageal junction cancers must have failed&#xD;
                  approved HER2-targeted agents.&#xD;
&#xD;
               -  Other HER2-positive tumor types must have failed standard of care therapies,&#xD;
                  while prior therapy with anti-HER2 drugs is not required.&#xD;
&#xD;
          -  Subject must be willing and able to undergo tumor tissue biopsy procedures&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          -  Subject has adequate bone marrow and organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV, active hepatitis B or hepatitis C infection.&#xD;
&#xD;
          -  Diagnosis of immunodeficiency or chronic exposure to systemic corticosteroid therapy&#xD;
             or any other form of immunosuppressive therapy&#xD;
&#xD;
          -  Untreated or symptomatic central nervous system (CNS) metastases or cytology proven&#xD;
             carcinomatous meningitis.&#xD;
&#xD;
             o Subjects with small, asymptomatic CNS metastases that do not require treatment are&#xD;
             permitted to enroll.&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt;50% as determined by ECHO or multiple gated&#xD;
             acquisition scan (MUGA)&#xD;
&#xD;
        Other protocol-defined Inclusion/Exclusion may apply.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debora Barton, MD</last_name>
    <role>Study Director</role>
    <affiliation>Carisma Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chief Medical Officer</last_name>
    <phone>267-491-6422</phone>
    <email>debora.barton@carismatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Yuan, MD</last_name>
      <phone>833-310-2278</phone>
      <email>yuanyuan@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng</last_name>
      <phone>919-445-4208</phone>
      <email>catherine_cheng@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciminera</last_name>
      <phone>215-220-9678</phone>
      <email>krista.ciminera@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Alexander</last_name>
      <phone>713-792-9137</phone>
      <email>Aalexand@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, Cummins KD, Shen F, Shan X, Veliz K, Blouch K, Yashiro-Ohtani Y, Kenderian SS, Kim MY, O'Connor RS, Wallace SR, Kozlowski MS, Marchione DM, Shestov M, Garcia BA, June CH, Gill S. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020 Aug;38(8):947-953. doi: 10.1038/s41587-020-0462-y. Epub 2020 Mar 23.</citation>
    <PMID>32361713</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2-positive solid tumors</keyword>
  <keyword>Phase 1</keyword>
  <keyword>cell therapy</keyword>
  <keyword>CAR-macrophage</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>advanced cancer</keyword>
  <keyword>post menopausal</keyword>
  <keyword>premenopausal</keyword>
  <keyword>metastatic cancer</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Lung Cancer, Small Cell</keyword>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Lung Cancer, Non-Small Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

